Crossmark

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Crossref DOI link: https://doi.org/10.1038/s41409-023-02160-8

Published Online: 2024-01-31

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beksac, Meral https://orcid.org/0000-0003-1797-8657
Eikema, Diderik-Jan

Koster, Linda

Hulin, Cyrille

Poiré, Xavier https://orcid.org/0000-0003-1897-0227
Hamladji, Rose-Marie

Gromek, Tomasz

Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Ozkurt, Zubeyde Nur

Pabst, Thomas https://orcid.org/0000-0002-6055-5257
Ben Othman, Tarek

Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Pirogova, Olga

Wu, Depei

Hayat, Amjad

Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Tholouli, Eleni

de Wreede, Liesbeth C. https://orcid.org/0000-0002-7667-9369
Schönland, Stefan https://orcid.org/0000-0002-4853-5579
Garderet, Laurent

Drozd-Sokolowska, Joanna

Raj, Kavita https://orcid.org/0000-0002-8258-354X
Hayden, Patrick J. https://orcid.org/0000-0003-1374-4503
Yakoub-Agha, Ibrahim

McLornan, Donal P. https://orcid.org/0000-0003-1224-091X
License Information

Text and Data Mining valid from 2024-01-31

Version of Record valid from 2024-01-31
More Information

Article History

Received: 4 September 2023

Revised: 3 November 2023

Accepted: 21 November 2023

First Online: 31 January 2024

Competing interests

: Authors declare no conflict of interest related to the current study. Only EBMT resources have been utilized in the analysis.

Document is current

Any future updates will be listed below